Antithrombotic Drug Therapy in Cardiovascular Disease (Contemporary Cardiology)

Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, __Antithrombotic Drug Therapy in Cardiovascular Disease__ carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticogulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, __Antithrombotic Drug Therapy in Cardiovascular Disease__ presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT). Front Matter....Pages i-xi Front Matter....Pages 1-1 Platelets in Arterial Thrombosis....Pages 3-17 The Role of Coagulation in Arterial and Venous Thrombosis....Pages 19-38 The Link Between Inflammation and Thrombosis....Pages 39-61 The Genetics of Thrombosis....Pages 63-114 Front Matter....Pages 116-116 Aspirin in Primary and Secondary Prevention of Cardiovascular Disease....Pages 117-129 Thienopyridines in Stable Coronary Disease....Pages 131-141 Front Matter....Pages 144-144 Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction....Pages 145-163 Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes....Pages 165-181 Direct Thrombin Inhibitors in Acute Coronary Syndromes....Pages 183-201 Synthetic Factor Xa Inhibition in Acute Coronary Syndromes....Pages 203-215 Front Matter....Pages 219-219 Antiplatelet Therapies: Aspirin, Clopidogrel and Thienopyridines, and Glycoprotein IIb/IIIa Inhibitors for the Management of ST-Segment Elevation Myocardial Infarction....Pages 219-233 Antithrombin Therapy for Acute ST-Segment Elevation Myocardial Infarction....Pages 235-246 Fibrinolysis and Facilitated PCI....Pages 247-257 Front Matter....Pages 260-260 Antithrombotic Therapy in Percutaneous Coronary Intervention....Pages 261-282 Antithrombotic Therapy in Carotid and Peripheral Intervention....Pages 283-305 Monitoring of Antithrombotic Therapies in Interventional Cardiology....Pages 307-328 Front Matter....Pages 330-330 Venous Thromboembolism....Pages 331-350 Fibrinolysis for Pulmonary Embolism....Pages 351-361 Duration of Anticoagulant Therapy After Venous Thromboembolism....Pages 363-385 Front Matter....Pages 388-388 Antithrombotic Therapy for Atrial Fibrillation and Cardioversion....Pages 389-403 Front Matter....Pages 388-388 Antithrombotic Therapy for Valvular Heart Disease....Pages 405-423 Antithrombotic Therapy in Heart Failure and Cardiomyopathy....Pages 425-433 Heparin-Induced Thrombocytopenia....Pages 435-447 Resistance to Antiplatelet Drugs....Pages 449-464 Back Matter....Pages 465-475 Substantial morbidity and mortality remains associated with thrombotic events has stimulated the rapid expansion of the available armamentarium to combat pathologic thrombosis. Pathologic thrombosis plays an essential role in the pathogenesis of acute coronary syndromes (ACS), ischemic complications of percutaneous coronary intervention (PCI), venous thromboembolic disease, and embolic complications of arrhythmias and various cardiomyopathies. Written by experts in the field, Antithrombotic Drug Therapy in Cardiovascular Disease carefully examines individual and various combinations of the available antithrombotic regimens including fibrinolytic agents, antiplatelet therapies (aspirin, thieneopyridines, glycoprotein IIb/IIIa inhibitors), and anticoagulant therapies (unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors), non-ST-segment elevation (NSTE) ACS and ST-segment elevation myocardial infarction (STEMI). A detailed overview, Antithrombotic Drug Therapy in Cardiovascular Disease presents the evidence demonstrating the efficacy of available antithrombotic therapies in specific disease states such as atrial fibrillation, cardiomyopathy, valvular heart disease, and heparin-induced thrombocytopenia (HIT). Written by experts in the field, this book provides a comprehensive overview of the pathophysiology, including the genetics, of arterial and venous thrombosis. It also presents the evidence demonstrating the efficacy of available antithrombotic therapies.